Remove 2027 Remove FDA Remove Pharmaceutical Companies
article thumbnail

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

FDA 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.

article thumbnail

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

billion between 2022 to 2027. Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio.

article thumbnail

Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty

Pharmaceutical Technology

The FDA approved both drugs in 2014. In an email , a Pliant spokesperson told Pharmaceutical Technology , “As currently approved therapies are not well tolerated, a new agent with a favorable safety profile and demonstrated efficacy would be a welcome addition to the IPF treatment armamentarium”.

FDA 59
article thumbnail

How much is Nexplanon without insurance?

The Checkup by Singlecare

The patent protection for Nexplanon typically prevents other pharmaceutical companies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Most insurance companies offer health insurance plans that cover Nexplanon and other birth control methods.